Medicament and method for reducing alcohol and/or tobacco consumption
CA 2495418 A1 · Owner: Hf Arzneimittelforschung Gmbh · Inventors: Opitz, Klaus; Moormann, Joachim; Mucke, Hermann
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a medicament for the treatment of dependent craving characterised in that the medicament comprises a combination of two dosage forms, whereby the one dosage form continuously releases at least one nicotinic receptor modulator and the other dosage form permits a rapid presentation of galanthamine into the central nervous system and a two-stage method for the therapy of substance craving by modulation of neuronal nicotinic receptors, in which a permanent treatment by means of a pharmaceutical dosage form which continuously releases a nicotinic receptor modulator on occurrence of strong substance craving is supplemented by the , administration of galanthamine or …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 25, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 25, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 25, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.